Indaptus Therapeutics Statistics
Share Statistics
Indaptus Therapeutics has 16.03M
shares outstanding. The number of shares has increased by 68.98%
in one year.
| Shares Outstanding | 16.03M |
| Shares Change (YoY) | 68.98% |
| Shares Change (QoQ) | 20.1% |
| Owned by Institutions (%) | 6.71% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 38 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 131.09K, so 0.91% of the outstanding
shares have been sold short.
| Short Interest | 131.09K |
| Short % of Shares Out | 0.91% |
| Short % of Float | 1.99% |
| Short Ratio (days to cover) | 1.66 |
Valuation Ratios
The PE ratio is -0.52 and the forward
PE ratio is -0.75.
Indaptus Therapeutics's PEG ratio is
0.04.
| PE Ratio | -0.52 |
| Forward PE | -0.75 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 2 |
| P/FCF Ratio | -0.64 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Indaptus Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.95,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.95 |
| Quick Ratio | 1.95 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,146,003.86 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -75.12% in the
last 52 weeks. The beta is 1.26, so Indaptus Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | -75.12% |
| 50-Day Moving Average | 0.64 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 38 |
| Average Volume (20 Days) | 426,652 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.37M |
| Net Income | -15.02M |
| EBITDA | -15.37M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.61 |
Full Income StatementBalance Sheet
The company has 5.79M in cash and 84.16K in
debt, giving a net cash position of 5.7M.
| Cash & Cash Equivalents | 5.79M |
| Total Debt | 84.16K |
| Net Cash | 5.7M |
| Retained Earnings | -60.44M |
| Total Assets | 7.34M |
| Working Capital | 3.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12.32M
and capital expenditures 0, giving a free cash flow of -12.32M.
| Operating Cash Flow | -12.32M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.32M |
| FCF Per Share | -1.32 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
